- Home
- OP vs EQ Comparison
OP vs EQ Comparison
Compare OP & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- EQ
- Stock Information
- Founded
- OP 2021
- EQ 2017
- Country
- OP Greece
- EQ United States
- Employees
- OP N/A
- EQ 35
- Industry
- OP
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- EQ Health Care
- Exchange
- OP Nasdaq
- EQ Nasdaq
- Market Cap
- OP 14.3M
- EQ 13.1M
- IPO Year
- OP N/A
- EQ 2018
- Fundamental
- Price
- OP $0.19
- EQ $0.40
- Analyst Decision
- OP
- EQ Buy
- Analyst Count
- OP 0
- EQ 3
- Target Price
- OP N/A
- EQ $3.00
- AVG Volume (30 Days)
- OP 16.4M
- EQ 553.1K
- Earning Date
- OP 08-06-2025
- EQ 08-07-2025
- Dividend Yield
- OP N/A
- EQ N/A
- EPS Growth
- OP N/A
- EQ N/A
- EPS
- OP N/A
- EQ N/A
- Revenue
- OP $25,702,000.00
- EQ $30,406,000.00
- Revenue This Year
- OP N/A
- EQ N/A
- Revenue Next Year
- OP N/A
- EQ N/A
- P/E Ratio
- OP N/A
- EQ N/A
- Revenue Growth
- OP 35.58
- EQ N/A
- 52 Week Low
- OP $0.17
- EQ $0.27
- 52 Week High
- OP $3.17
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- OP 33.59
- EQ 56.38
- Support Level
- OP $1.49
- EQ $0.36
- Resistance Level
- OP $2.50
- EQ $0.45
- Average True Range (ATR)
- OP 0.26
- EQ 0.06
- MACD
- OP -0.18
- EQ 0.00
- Stochastic Oscillator
- OP 0.73
- EQ 59.32
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.